Mineralys Therapeutics(MLYS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is ramping up enrollment under the amended protocol and is anticipated to deliver topline data in 1H 2025 – – Conference ca ...